JOAQUÍN
MARTÍNEZ LÓPEZ
Catedrático de universidad
University of Turin
Turín, ItaliaPublicacions en col·laboració amb investigadors/es de University of Turin (8)
2023
-
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe
Future Oncology, Vol. 19, Núm. 31, pp. 2103-2121
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2019
-
Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377
2017
-
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma
Blood, Vol. 129, Núm. 16, pp. 2233-2245
2016
-
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
Leukemia, Vol. 30, Núm. 9, pp. 1844-1852
2013
-
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 14, Núm. 11, pp. 1055-1066